News Stories

The National Lipid Association (NLA), in collaboration with the American Society for Preventive Cardiology (ASPC), has released a Joint Expert Clinical Consensus providing new guidance on the recognition and management of persistent chylomicronemia — a severe and often misunderstood form of hypertriglyceridemia. The full paper is now published in the Journal of Clinical Lipidology and available here.

Novartis received FDA approval for a label update that will allow for use of Leqvio ^® (inclisiran) in certain patients at high risk of cardiovascular (CV) disease. This broader population allows for earlier Leqvio treatment in patients with elevated low-density lipoprotein cholesterol (LDL-C) and CV risk factors, such as diabetes and hypertension, who are at increased risk of atherosclerotic cardiovascular disease (ASCVD), beyond the previously approved ASCVD and heterozygous familial hypercholesterolemia (HeFH) patient population.